NCT04522544
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04522544
Title Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Acronym IMMUWIN
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Universitätsklinikum Bonn Bonn 53127 Germany Details
Universitätsklinikum Köln Cologne 50937 Germany Details
Universitätsklinikum Essen Essen 45147 Germany Details
Universitätsmedizin Göttingen Göttingen 37075 Germany Details
Medizinische Hochschule Hannover Hanover 30625 Germany Details
Universitätsklinikum Jena Jena 07747 Germany Details
Universtitätsklinikum Schleswig-Holstein Lübeck 23538 Germany Details
Klinikum rechts der Isar der Technischen Universität München München 81675 Germany Details
München Klinik Bogenhausen München 81925 Germany Details
Universitätsklinikum Münster Münster 48149 Germany Details
Universitätsklinikum Tübingen Tübingen 72076 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field